
Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …

Eisai is hoping that existing neurology drug mecobalamin can be a new option for the difficult-to-treat condition amyotrophic lateral sclerosis …

